Ekdv-691 Better May 2026
The keyword EKDV-691 refers to a specific adult film production from the Japanese adult video (JAV) industry. Released in September 2022, it is part of the E-Kiss series produced by the studio Crystal Eizou. Production Details
Stay tuned for the official GA announcement in Q2 2026, and consider signing up for the early‑access developer program on the Ekard website. The quantum‑ready future is just around the corner—let’s be ready for it. EKDV-691
- Background, objectives, methodology, results, discussion, conclusions, recommendations, next steps, risks, budget, timeline, etc.
4. Clinical Development
4.1. Phase I – First‑in‑Human (FIH)
| Parameter | Details |
|-----------|---------|
| Design | Randomized, double‑blind, placebo‑controlled, single‑ascending dose (SAD) and multiple‑ascending dose (MAD) in healthy volunteers (n = 72) |
| Doses | SAD: 1 mg → 200 mg; MAD: 5 mg → 100 mg q.d. for 14 days |
| Primary endpoints | Safety, tolerability, PK |
| Secondary endpoints | PD biomarkers (p‑SMAD2/3 in PBMCs, serum PRO‑C3) |
| Key outcomes | - No serious adverse events (SAEs).
- Most common TEAEs: mild headache (12 %), transient nausea (8 %).
- Linear PK up to 100 mg; exposure proportional to dose.
- PD: ≥ 70 % inhibition of p‑SMAD2/3 at 30 mg; sustained PRO‑C3 reduction ≥ 45 % at 60 mg. |
| Conclusion | EKDV‑691 was well tolerated with a clear exposure‑PD relationship, supporting progression to patient studies. | The keyword EKDV-691 refers to a specific adult
